Accuray (ARAY) Expected to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is expected to be releasing its earnings data before the market opens on Wednesday, January 29th. Analysts expect Accuray to post earnings of ($0.02) per share and revenue of $110,360.00 billion for the quarter. Accuray has set its FY 2025 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The firm had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. During the same period in the previous year, the company posted ($0.03) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Stock Down 2.6 %

Shares of Accuray stock opened at $2.22 on Tuesday. Accuray has a 1 year low of $1.40 and a 1 year high of $2.95. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The stock has a market cap of $223.27 million, a price-to-earnings ratio of -13.06 and a beta of 1.47. The firm’s 50-day moving average is $2.05 and its two-hundred day moving average is $1.95.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.